ARTICLE | Emerging Company Profile
Archon: Tuning antibodies through geometry
Latest spinout from David Baker’s IPD rescuing failed mAbs by forcing them into cage-like structures for better biodistribution, target engagement
November 15, 2024 12:02 AM UTC
Archon is packing antibodies into computationally designed geometries to better control their activity, with the goal of addressing well-understood targets failed by free mAbs.
The company, which emerged from stealth Oct. 30 with a $20 million seed round led by Seattle-based Madrona Ventures, is the latest in a long line of spinouts from University of Washington’s Institute for Protein Design (IPD), which is helmed by 2024 Nobel Prize in Chemistry winner David Baker...